Scar Zone Labeling Issues Referred To FDA Following NAD Compliance Review
This article was originally published in The Rose Sheet
Executive Summary
FDA is considering regulatory action against CCA Industries regarding certain labeling claims made on the firm's Scar Zone topical scar diminishing cream. The product is part of the Sudden Change skin care line
You may also be interested in...
CCA Industries Scar Zone Drug Facts Labeling Changes Urged By NAD
CCA Industries should remove references to cosmetic scar reduction benefits in the "Uses" and "Purposes" sections of the OTC Drug Facts labeling on packaging for Sudden Change Scar Zone cream, the National Advertising Division of the Council of Better Business Bureaus concludes in a recent inquiry
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle